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Abstract   
Background 
During pulmonary tuberculosis (PTB) antibodies are generated to trehalose esters of mycolic acids which are cell wall lipids 
of Mycobacterium tuberculosis (Mtb).  Attempts have been made to use these complex natural mixtures in serological tests 
for PTB diagnosis.   
Aim 
The aim of this work was to determine whether a serological test based on a panel of defined individual trehalose esters of 
characteristic synthetic mycolic acids has improved diagnostic accuracy in distinguishing patients with culture positive PTB  
from individuals who were Mtb culture negative.  
Method 
One hundred serum samples from well-characterized patients with presumptive tuberculosis, and diagnosed as having 
pulmonary smear and culture positive TB, or being culture and smear negative were evaluated by ELISA using different 
combinations of synthetic antigens and secondary antibodies. Using cut-off values determined from these samples, we 
validated this study blind in samples from a further 249 presumptive TB patients. 
 
Results 
With the first 100 samples, detailed responses depended both on the precise structure of the antigen and on the secondary 
antibody. Using a single antigen, a sensitivity/specificity combination for smear and culture positive PTB detection of 85 and 
88% respectively was achieved; this increased to 96% and 95% respectively by a statistical combination of the results with 
seven antigens. In the blind study a sensitivity/specificity of 87% and 83% was reached with a single antigen. With some 
synthetic antigens, the responses from all 349 samples were significantly better than those with the natural mixture. Combining 
the results for seven antigens allowed a distinction between culture positive and negative with a ROC AUC of 0.95.   
 
Conclusion 
We have identified promising antigen candidates for serological assays that could be used to diagnose PTB and which could 
be the basis of a much-needed, simple, rapid diagnostic test that would bring care closer to communities.      
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Introduction 
  
Despite advances in the development of diagnostics for pulmonary tuberculosis (PTB), poor case-detection rates remain an 
obstacle to its control in many low and middle-income countries.  Access to any kind of current diagnostic service remains a 
problem for significant sections of society [1].  Even when accessible, smear microscopy (still the most commonly used PTB 
diagnostic) has a poor sensitivity and about half the PTB cases that are tested may be a false negative.  The newer molecular 
diagnostic tests for PTB are much more sensitive but, due to the infrastructure required for the equipment, the test facility 
tends to be centralised and becomes even less accessible to the poorer and more marginalized; their performance remains 
under review [2]. New tests are needed to allow rapid diagnosis closer to affected communities [3,4],  the ideal being a robust, 
simple serological test that could dramatically improve PTB detection.  Such a test has proved elusive. The complexity and 
variability of the antigenic make-up of Mycobacterium tuberculosis (Mtb), of the host immunological response to the organism 
and the chronic, fluid nature of Mtb, infection and disease all present challenges [5].  An additional challenge has been the 
lack of well-defined Mtb antigens in sufficient quantities.  Either large quantities of poorly defined or undefined mixed antigens, 
or very small quantities of well-defined extracted antigens, were available. These inadequacies in antigen resources have 
compromised the development of reproducible assays, and hampered our ability to understand the immunology of infection 
and disease.     
Recently, it has been shown that B cells are functionally altered through the course of tuberculosis (TB), opening new 
challenges to our understanding on their role in TB pathogenesis [6].  There have been extensive reviews of serodiagnostic 
assays for TB [7-11]. The World Health Organisation (WHO) has recently summarised a large number of such assays; it 
indicated that none of these reach the standards of specificity and sensitivity required [12], but identified a clear requirement 
for a fast and robust serodiagnostic test for point of care use that does reach the required standards. It has defined the target 
product profile for such an assay [13]. Various studies, e.g. [14-16], have described heterogeneity in responses during infection 
and disease, and indeed temporal differences in the nature of the responses through the course of infection/disease. A 
successful serological assay for the diagnosis of TB is likely to be based on a matrix of reactions to a panel of key antigens 
[17], perhaps differentiated on the basis of the immunoglobulin class involved.     
Several antigens have been examined and numerous analyses of serodiagnostic assays have been produced [18 – 26]. The 
use of natural lipid antigens extracted from Mtb cells in serodiagnosis has been reported, primarily by two groups. These 
antigens, present in the cells of mycobacteria and some related organisms, contain long chain ‘mycolic acids’ (MA) (1), which 
are generally either bound to the cell wall as esters or as, eg., non-wall-bound trehalose dimycolates (2) (TDM, ‘cord factor’) 
and monomycolates (TMM) (3) (Fig 1) [27 – 29]. They are present as complex mixtures of different carbon chain lengths as 
well as different structural sub-classes (mainly α-, methoxy and keto- in Mtb) that can form a fingerprint of a particular 
Mycobacterium. The first diagnostic method, using as antigens complex mixtures of TDM (2), isolated from Mtb, by ELISA has 
been reported by Yano [30 – 41]. The highest average response was for smear-positive PTB patients, followed by atypical 
mycobacteriosis and then by the smear-negative PTB patients.  Serum from healthy controls and cancer patients did not 
generate responses, leading to an overall sensitivity of 84% and specificity of 100% [30]. The results using IgM as the 
secondary antibody were less clear. In those treated for PTB, the response declined during treatment, reaching the level of 
controls after 3 years [32]. Despite excellent reported sensitivity and specificity, obtained primarily using samples from Japan, 
the method was among those not supported for use by the WHO [12]. The second method, reported by Verschoor uses 
complex mixtures of free MAs (1) derived by hydrolysis of the mycolate esters present in the cells [42 – 46]. In this case, the 
accuracy in ELISA is rather lower [47], but significantly improved by using a more complex biosensor system [43 – 46].  
Nonetheless, one advantage of both this and the Yano method is that the antigen-antibody interactions are retained in TB/HIV 
co-infected patients [31]. The detailed composition of the complex mixtures of individual lipids, MAs (1) and their TDMs (2) 
and TMMs (3) (Fig 1), changes during the progression of disease and with the virulence of the mycobacterial strain [48-50]. 
Moreover, similar, but characteristic, mixtures of MAs are present in other mycobacteria, including common environmental 
mycobacteria, and in a number of related organisms such as Rhodococcus [51,52]. One hypothesis for the failure of these 
two methods to reach the required standards of accuracy is that serum from patients without TB may be cross-reacting with 
Mtb antigens as a result of patients’ previous exposure to  mycobacteria other than Mtb, or that the antibodies present at the 
disease stage at which the serum was taken do not match the antigen mixture used for diagnosis. A further complication may 
be that overall antibody levels change during disease progression or that responses to antibodies to lipids are heterogeneous 
[53,54].  Many people, though infected with Mtb, do not develop TB disease and are said to have latent TB infection (LTBI). It 
may be that some antibodies to lipids are generated during LTBI, and this leads to false positives in diagnosing TB disease 
[55]. 
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Fig 1: A general mycolic acid structure (1), together with TDM (2) and TMM (3). Abbreviations: Y, the proximal group, is 
normally either a cis-cyclopropane, a trans-cyclopropane with a methyl substituent on the adjacent carbon distal from the 
hydroxy-acid, a cis-alkene, or a trans-alkene with a methyl substituent on the adjacent carbon proximal to the hydroxy-acid. 
X, the distal substituent, is normally a cis-cyclopropane (α-MAs), a -CH(CH3)CH(OCH3)- group (methoxy-MAs) or a –
CHCH3CO- group (keto-MAs) 
 
Natural TDMs from different classes of MA show differential responses in assays for TB [36]. Given the effect of the balance 
of these classes, and of stereochemistry within the classes, on disease profile [48-50], one possibility for increasing the 
accuracy of such assays is to use a diagnostic device based on a set of highly defined antigens, single synthetic sugar esters 
of MA matching individual components of either Mtb or of other mycobacteria [56-59].  
 
This paper describes an evaluation of these synthetic lipid antigens as diagnostic markers for smear and culture positive PTB 
in comparison with TDM extracted from Mtb cells and, for comparison, bovine TDM (the latter was included to determine 
whether there were any significant differences in response caused by a different balance in the complex mixtures of MA and 
TDM between human and bovine samples). It explores the heterogeneity of immunological responses to these antigens 
among people   with presumptive TB [60] in disease-endemic countries; it identifies patterns of Ag/Ig class reactions 
associated with confirmed pulmonary TB; and it evaluates the use of such patterns to predict confirmed PTB in a set of well-
characterized blinded specimens. It seeks to determine whether combining the results of a set of such assays with different 
antigens can improve diagnostic performance to a level which, when applied on an appropriate platform, might meet the 
requirements set for a point of care assay [12,13]. 
 
 
Materials and Methods 
Study design.  
TDR TB Specimen Bank provided serum specimens that had been collected with all the necessary ethical approval and patient 
consent for distribution to diagnostic test developers [61]. Patients had presented at healthcare facilities in different countries 
with symptoms suggestive of pulmonary TB (PTB). In this study, those having PTB were positive on culture, and those not 
having PTB were negative on culture.  
 
Within the study format given in Fig 2, these samples were divided into 3 sub-sets. The clinical characteristics of the first two 
sets of 50 serum samples (n = 100) are given in Tables 1 and 2.  These samples were used to develop the assay and were 
not tested blind.  Having developed the assay using these sets, we validated it through blinded testing of a further 249 samples 
provided from TDR without any accompanying data (Table 3).  The results were analysed using cut-off values set for the first 
100 samples.  WHO/TDR only un-blinded the analysis once results had been reported to them. The results from all 349 
samples were considered together in order, where data were available, to analyse the various sub-groups, such as previous 
TB, positive TST, BCG vaccination, other active diseases, and country effects (Supplementary Data). However it should be 
noted that data on TST, BCG and other diseases were not complete and not collected in a standardised way across sites due 
to differences in practices between countries and to limited capacity for the diagnosis of other diseases in many of the 
countries.    
  
Fig 2: Study format. Abbreviations:  TB: tuberculosis; BCG: Bacillus Calmette–Guérin; TST: tuberculin skin test; u/k: 
unknown.  
The serum samples.  
The TDR TB Specimen Bank [61] samples were collected from 349 patients with respiratory symptoms suggestive of PTB in 
10 countries.  No specific treatment had been started in any of the patients enrolled. Detailed information was available on 
the patient profile, the country of origin, and the symptoms, as well as the microbiology on solid and/or liquid culture, and, in 
some cases of follow-up observations. Clinical data also included chest X-ray, where available. Of the 349 patients, 102 had 
culture positive PTB. Of these 100 were also smear positive (Fig 2; Table 1-3). The 247 patients who were considered not to 
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have PTB were all culture negative.  Four of these patients gave  weakly positive smears but nevertheless were considered 
not to have PTB on the basis of negative cultures.  All culture negative patients were followed up for two months and found 
still to be negative. Eleven of the negatives were given treatment and three improved, five showed no change, one was 
worse and for two there was no follow up. Investigations included repeat cultures if the respiratory symptoms had persisted. 
Approximately twice as many negative specimens as positive specimens were provided, because of the development and 
early validation aims of the study.  
  
Table 1: Demographic and clinical characteristics of the first 50 patients whose sera were evaluated  
 TB No TB   
 Culture positive Culture negative Total p value 
 N. 10 N. 40 N. 50  
Age median   (IQR)  28.5 (23 – 40) 40 (25 – 54) 38.0  (24 – 50.5) .0183 
Sex, MALE  
  N (%)  
7 (70%)  22 (55)  29 (58) 0.389 
AFB smear score/total (%) Score 0:   0 Score 0:   38  (95) Score 0/ 38 (76) <0.001 
 Score 1:   4(40) Score 1:   2 (5) Score 1/ 6 (12)  
 Score 2:   3(30)  Score 2/ 3 (6)  
 Score 3:   3(30)  Score 3/ 3(6)  
Solid and/or liquid culture positive 10 (100) 0 10 (20) NA 
BCG vaccination recorded       N (%) 7 (70)  22 (55) 29 (58) 0.380 
Previous TB reported               N (%) 1 (10)  6 (15) 7 (14) 0.504 
Other diseases                         N (%) 2 (20)  7 (17.5) 9 (18)  
Site           Pulmonary 8 (80) 40 (100) 48 (96) 0.178 
                 Extra-pulmonary/pulmonary  1 (10) 0 1 (2)  
                 Unknown 1 (10) 0 1 (2)  
Region of Origin                       N (%) Asia 5 (50) Asia 13 (32.5)    Asia 18 (36)    <0.001 
 Africa 5 (50) Africa 7 (17.5) Africa 12 (24)  
  S. America 20 (50) S. America 20 (40)  
  
Table 2: Demographic and clinical characteristics of the second 50 patients whose sera were evaluated.  
 TB No TB   
 Culture 
positive 
Culture negative Total p value 
 N. 17 N. 33 N. 50  
Age median (IQR) 35 (25.5 - 43.5) 41 (33 – 49.5)  38 (28.5 – 46.5) 0.233 
Sex, MALE 
  N (%)  
10 (59) 14 (42) 24 (48) 0.189 
AFB smear score/total (%) Score 0:   0  Score 0:   32 (97) Score 0:   32 (64) <0.001 
 Score 1:   3(18),  Score 1:   1(3), Score 1:   4 (8),   
 Score 2:   10(59)  Score 2:   10 (20),   
 Score 3:   4(23)  Score 3:   4 (8)  
Solid and/or liquid culture positive 17(100) 0 17 (34) NA 
BCG vaccination recorded            N 
(%) 
9 (53)   
 
18 (54.5)  
 
27 (54) 
 
0.953 
 2 unknown 4 unknown 6 unknown  
Previous TB reported        N (%)   1 (6) 8 (24) 9 (18) 0.171 
Other diseases       N (%) 5 (17.5)   18 (54.5)  23 (46)  
Site            Pulmonary 16 (94)   33 (100)   49 (98)  
               Unknown 1    
TST       Positive 3 (17.5) 7 (21)   10 (20)  
              Negative  2 (11.8) 7 (21) 9 (18)  
              Not done 12 19   
Region of origin Africa (8)   Africa (9)  Africa (17)  <0.001 
 S. America (2)  S. America (13)  S. America (15)   
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 Asia (6)  Asia (0) Asia (6)  
 W.Europe (1) W. Europe (6) W. Europe (7)  
  N. America (5)   N. America (5)   
Footnotes:    TST: tuberculin skin test  
 
Table 3:  Demographic and clinical characteristics of the third set of patients: validation study performed on 249 
samples. 
 TB No TB   
 Culture positive Culture negative Total  p value 
 N. 75 N. 174   
Age median   (IQR) 29 (25 – 43) 47 (29 – 63) 37.5 (26 – 57.8) <0.001 
Sex, MALE                  N (%)  48 (64) 81 (46.5) 129 (52) <0.001 
AFB smear score/total (%) Score 0:   2 (3) Score 0:  173 (99) Score 0:   175 (70) <0.001 
 Score 1:   18 (24) Score 1:   1(1) Score 1:   19 (7.5)  
 Score 2:   17 (22.5)  Score 2:   17 (7)  
 Score 3:   38 (50.5)  Score 3:   38 (15)  
Solid and or liquid culture  positive 75(100) 0 (0) 75 (30.1) <0.001 
BCG vaccination recorded       N (%)                          21 (28)  60 (34.5)   81 (32.5) 0.001 
Unknown 4 36   
Previous TB reported   N (%)   13 (17)   35 (20) 48 (19) 0.552 
Other diseases     N (%)   26 (35)   113 (65) 139 (56)  
Site (number, percent)      Pulmonary 74 (98.5) 173 (99.5) 247 (99) 0.563 
         Extra-pulmonary + pulmonary 1 (1.5)   1 (0.5) 2 (1)  
TST                             Positive    6 (8)  45 (26) 51 (20.5) 0.216 
                                    Negative  1 (1.5) 42 (24) 43 (17)  
                                    Not done  68 87 155  
Region of origin Asia (24) Asia (5) Asia (29) <0.001 
 S. America (21) S. America (52)   S. America (73)    
  N. America (29) N. America (29)  
 Africa (27) Africa (58) Africa (85)  
 W. Europe (3) W. Europe (30)   W. Europe (33)    
Footnotes.    TST: tuberculin skin test 
 
The assay.  
ELISA were carried out on 96-well flat-bottomed polystyrene micro-plates by slight modification of methods reported earlier 
[31, 45]. Antigens were dissolved in hexane to give a concentration 15 µg/ml. 50 µl of this solution was added to each well, 
and the solvent was left to evaporate at room temperature. Control wells were coated with hexane (50 µl/well) only. Blocking 
was achieved by adding 400 µl of 0.5 % casein/PBS buffer (pH 7.4) to each well, and the plates were incubated at 25 ºC for 
30 minutes. The buffer was aspirated and any excess was flicked-out until the plates were dry. Serum (1 in 20 dilution in 
casein/PBS buffer, unless otherwise stated) (50 µl/well) was added and incubated at 25 ºC for 1 hour. The plates were 
washed with 400 µl casein/PBS buffer 3 times using an automatic washer, and any excess buffer was flicked out onto a 
paper towel until dry. Secondary antibody (all peroxidase conjugated; produced in goat, diluted in casein/PBS buffer, 50 
µl/well) [from Sigma Aldrich UK: A0170 (Anti-Human IgG (Fc specific),1:2000); A8667 (Anti-Human IgG (whole molecule), 
1:1000); A6029 (Anti-Human IgG (γ-chain specific), 1:2000); A6907 (Anti-Human IgM (μ-chain specific), 1:333); A0295 (Anti-
Human IgA (α-chain specific), 1:1667] was added, and incubated at 25 ºC for 30 minutes.  The plates were again washed 3 
times with 400 µl casein/PBS buffer using an automatic washer, and any excess buffer was again flicked out. OPD 
substrate (50 µl / well) (o-phenylenediamine (1 mg/ml) and H2O2 (0.8 mg/ml) in 100 mM citrate buffer) was then added, and 
the plates were incubated for a further 30 minutes at 25 ºC. The colour reaction was terminated by adding 2.5 M H2SO4 (50 
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µl/well), and the absorbance was read at 492 nm. Each measurement was carried out in quadruplicate and an average was 
taken. 
The results presented are the un-modified absorbance figures recorded at 492 nm and, do not have the absorbance at 630 
nm, or the blank for a plate with no serum subtracted (S1 Table).    
 
The antigens.  
Natural human and bovine TDM were purchased from Sigma-Aldrich UK. Synthetic antigens were prepared as previously 
described [56 – 59]. Their structures are given in Table 4. 
Table 4: Synthetic trehalose dimycolates (TDMs), trehalose monomycolates (TMMs) and model TDMs used.  
 Derived TDM Derived TMM 
Mycolic acid Compound number Reference Compound number Reference 
 
4 54 5 54 
 
6 54 7 54 
 
8 55 9 55 
 
10 55 11 55 
 
12 54 13 54 
 
14 54 15 54 
 
16 54 17 54 
26 
18 54 19 54 
 
20 54 21 54 
 
22 56   
     
CH3(CH2)22COOH 23 55   
     
 
CH3(CH2)20COOH 
 
24 
   
  55   
 
(mixed TDM with α- and methoxy-MA) 
25 54   
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Statistical methods.   
Statistical testing of the sample demographics was carried out using the coin package in R using an exact Wilcoxon-Mann-
Whitney test for continuous data and a Chi-Squared test based on a Monte Carlo resampled distribution for the contingency 
data [62]. For the data analysis based on multiple antigen response and disease status, a training set was formed from the 
first two data sets (in total 100 samples, with 27 smear and culture positive PTB cases). Validation was done from the third 
data set in which the disease status was blind at the time of classification. Classification of PTB status based on assay 
response levels was estimated using tree based Random Forest and Generalised Boosted Model (GBM) classifiers [63,64], 
trained with the training set in R [65]. An initial screen of the antigens selected those showing a variation of response across 
the cases and evidence of discrimination between TB status. From the training, a subset of 7 of antigens was selected based 
on variable importance and a new classifier estimated from the training set using only these antigens. Predictions of disease 
status were then made for the validation data using this classifier. ROC curves and AUC values were estimated with the pROC 
package [66] in R [6]. Significance of pairwise differences between AUC values was estimated using the DeLong’s test [67] 
implemented in the pROC R package. Optimal diagnostic cut-off points were determined using Youden’s J statistic which 
maximises sensitivity + specificity. 
 
Results   
The experimental ELISA was based on TDMs (structures 2) or TMMs (structures 3) (Fig 1, Table 4) prepared from single 
synthetic MAs containing specific combinations of cis- or trans-cyclopropane and different oxygenated functionality, patterns 
known to have different effects on innate immune system responses and to change disease virulence [48 – 50].  
 
Results for the initial 50 serum samples. 
Natural human and bovine TDM and a number of synthetic TDMs and TMMs were examined using a set of 50 serum samples 
and, in some cases, several different secondary antibodies.    Commercial natural human (n15) and bovine TDM (n20) gave 
significantly different medians with smear and culture positive PTB  and culture negative sets using IgG (whole) secondary 
antibody (p <.001), and AUCs of 0.86 and 0.88 on ROC analysis (Table 5; S2 Fig). The human TDM gave slightly lower AUCs 
with IgG(Fc) (0.82) and IgG(gamma) (0.80) secondary antibodies, though the medians were significantly different (p = 0.001 
and 0.003). The medians for the two sets (S3 Fig) were not significantly different with IgM and IgA secondary antibody (n18 
and n19) (p=0.616 and 0.050) and the AUCs were lower (0.55 and 0.70) (Table 5).   
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Table 5: Results of the ELISA with first set of 50 human sera (10 Mtb culture positive PTB and 40 Mtb culture negative patients) using the different antigen/antibody combinations  
    TB No TB     
Type of 
compound¥¥ 
 
Compound 
number 
Method# 2nd Ab 
used 
Smear and culture  
positive PTB  ## 
Culture negative## p value of the 
comparisons of 
medians ELISA 
results from 
culture positive 
PTB 
 and culture 
negative samples 
 
ROC AUC¥ 
 
(95 % interval) 
 
 
Optimum 
Cut-off 
from ROC 
 
Sensitivity/ 
Specificity 
from 
optimum 
ROC cut-off 
    Median Absorbance 
(IQR) 
Median Absorbance 
(IQR) 
 Significance relative 
to n15 
  
Human TDM Natural mixture n15 IgG 3.12 (2.83 – 3.36) 2.03 (1.3 – 2.77) <0.001 0.86  (0.74-0.99) 2.79 80/80 
 Natural mixture n16 IgG(Fc) 2.6 (1.46 – 2.91) 0.95 (0.63 – 1.59) 0.001 0.82  (0.68-0.95) 1.41 80/68 
 Natural mixture n17 IgG(g) 2.84 (1.52 – 3.24) 1.21 (0.64 – 2.04) 0.003 0.80  (0.64-0.95) 1.96 70/73 
 Natural mixture n18 IgM 2.08 (0.98 -2.8) 2.3 (1.15 – 2.93) 0.616 0.55* (0.34-0.76) 1.79 50/63 
 Natural mixture n19 IgA 0.43 (0.29 – 1) 0.31 (0.2 - 0.37) 0.050 0.70  (0.52-0.89) 0.36 70/73 
Bovine TDM Natural mixture n20 IgG 3.02 (2.85 – 3.24) 1.93 (1.06 – 2.39) <0.001 0.88  (0.77-0.99) 2.79 90/85 
α TDM 4 n21 IgG 2.7 (1.34 – 3.35) 1.99 (1.45 – 2.76) 0.233 0.63** (0.39-0.86) 2.98 50/85 
α TMM 5 n22 IgG 3.11 (2.46 – 3.59) 1.91 (1.31 – 2.78) 0.001 0.81  (0.67-0.95) 2.40 80/65 
  α TDM 6 n23 IgG 3.06 (2.88 – 3.4) 2.19 (1.22 – 2.89) 0.001 0.82  (0.70-0.94) 2.81 90/68 
 6 n3 IgG(Fc) 3.1 (2.29 – 3.2) 0.96 (0.58 – 1.67) <0.001 0.89  (0.80-0.99) 1.70 90/78 
  α TMM 7 n24 IgG 2.94 (2.5 – 3.29) 1.79 (1.23 – 3.06) 0.040 0.71* (0.56-0.86) 2.18 90/55 
 7 n4 IgG(Fc) 2.31 (1.54 – 2.84) 1.01 (0.59 – 2.15) 0.027 0.73* (0.57-0.88) 1.44 80/58 
MeOTDM 12 n27 IgG 3.17  (2.64 – 3.35) 1.73 (1.18 – 2.8) <0.001 0.85  (0.73-0.97) 2.34 90/68 
 12 n28 IgG(Fc) 2.58 (1.97 – 2.75) 0.73 (0.49 – 1.32) <0.001 0.89 (0.76-1.00) 1.78 80/90 
 12 n29 IgM 3.07 (2.21 – 3.14) 2.98 (2.32 – 3.2) 0.961 0.50*** (0.30-0.69) 3.05 60/63 
 12 n30 IgA 1.39 (0.59 – 1.93) 0.6 (0.34 – 0.79) 0.017 0.74  (0.57-0.91) 1.19 60/90 
MeOTMM 13 n31 IgG 1.68 (1.09 – 3) 0.81 (0.65 – 1.17) <0.001 0.84  (0.71-0.97) 1.06 80/70 
 13 n32 IgG(Fc) 1.13 (0.65 – 3.05) 0.68 (0.5 – 1.15) 0.060 0.69 (0.48-0.90) 1.07 60/73 
 13 n33 IgM 1.72 (1.3 – 1.82) 1.52 (1.1 – 2.22) 0.982 0.50*** (0.30-0.70) 1.53 70/55 
 13 n34 IgA 0.51 (0.27 – 0.87) 0.27 (0.18 – 0.39) 0.0724 0.68 (0.49-0.88) 0.36 60/73 
 MeOTDM 14 n35 IgG 3.17 (2.99 – 3.44) 1.66 (0.85 – 2.82) <0.001 0.86  (0.75-0.98) 2.94 80/80 
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 14 n1 IgG(Fc) 3.48 (2.04 – 4.08) 0.76 (0.51 – 1.19) <0.001 0.94  (0.86-1.00) 1.34 90/83 
 14 n1b IgG(Fc) 0.88 (0.4 – 2.98) 0.32 (0.27 – 0.41) <0.001 0.86  (0.73-0.98) 0.39 80/67 
 MeOTMM 15 n2 IgG(Fc) 2.96 (1.83 – 3.74) 0.65 (0.47 – 1.18) <0.001 0.92  (0.85-1.00) 1.32 90/85 
 t-MeOTDM 16 n47 IgG(Fc) 1.06 (0.57 – 3.01) 0.38 (0.29 – 0.49) <0.001 0.90  (0.81-1.00) 0.50 90/75 
  t-MeOTMM 17 n36 IgG 2.68 (2.19 – 3.04) 1.13 (0.77 – 1.82) <0.001 0.87  (0.76-0.98) 1.99 80/78 
 17 n37 IgG(Fc) 2.08 (1.2 – 2.91) 0.58 (0.37 – 1.03) <0.001 0.88  (0.78-0.99) 1.07 80/78 
  t-ketoTDM 18 n38 IgG 2.07 (0.79 – 3.34) 0.81 (0.5 – 1.4) 0.026 0.73* (0.52-0.93) 1.68 60/80 
 18 n5 IgG(Fc) 2.79 (1.42 – 3.08) 0.91 (0.56 – 1.56) 0.001 0.82  (0.69-0.96) 1.93 70/83 
  t-ketoTMM 19 n6 IgG(Fc) 3.09 (2.16 – 3.87) 0.97 (0.6 – 1.76) <0.001 0.88  (0.78-0.99) 1.79 90/77 
  ketoTDM 20 n39 IgG(Fc) 3.09 (2.16 – 3.87) 0.97 (0.6 – 1.76) <0.001 0.95 (0.89-1.00) 1.88 90/89  
23 nx01 IgG 2.4 (1.35 – 3.25) 1.12 (0.8 – 1.69) 0.002 0.82  (0.68-0.96) 1.60 70/73  
24 nx02 IgG 3.09(2.92 – 3.42) 2.79 (2.45 – 3.24) 0.057 0.70* (0.54-0.85) 2.82 100/53 
Footnotes: # Method: combination of a compound and a secondary antibody; ## evaluations were done at a serum dilution of 1:20, except n1b and n47 at 1:80. In each case the secondary 
antibody was peroxidase conjugated and the binding was measured by addition of o-phenylenediamine and H2O2 in citrate buffer and the colour reaction was terminated by the addition of acid.  
¥ ROC analyses are presented in S2 Fig. Standard significance values indicated by stars (* P<0.05, ** P<0.01, *** P<0.001) are for comparisons of ROC results for each method relative to 
those for method n15. Significance of pairwise differences between AUC values was estimated using the DeLong’s test [67] implemented in the pROC R package. Ab: antibody, TDM: trehalose 
dimycolate, TMM: trehalose monomycolate ROC: receiver operator characteristics AUC: area under curve PTB: pulmonary tuberculosis IQR: interquartile range.   ¥¥ MeOTDM: TDM from cis-
cyclopropane containing methoxy-MA. MeOTMM: TMM from cis-cyclopropane methoxy-MA.  tMeOTDM: TDM from trans-cyclopropane methoxy-MA. tMeOTMM: TMM from trans-cyclopropane 
methoxy-MA. ketoTDM: TDM from cis-cyclopropane ketoMA. t-ketoTDM: TDM from trans-cyclopropane ketoMA. t-ketoTMM: TMM from trans-cyclopropane ketoMA. α TDM: TDM from α-MA. α 
TMM: TMM from α-MA. 
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Most of the single synthetic TDMs and TMMs gave AUC values above 0.8 when IgG or IgG(Fc) secondary antibody was used. 
Median responses and differences between medians for smear and culture positive PTB and culture negative samples were 
much lower and not significant for IgM or IgA. This is in line with results when using natural mixtures of TDMs [68, 69].  
Individual TDMs and TMMs from each of the common α-, methoxy and keto-classes in Mtb gave higher specificities than the 
natural mixtures. Within the classes, high AUCs were obtained with antigens having a range of different absolute 
stereochemistries about the different functional groups. Even the model compound 23 with no functionality in the α-chain of 
the MA (nx01) gave a significant difference between the medians for the two sets. The highest AUC of all (0.95) was obtained 
with the TDM 17 derived from a cis-cyclopropane containing keto-MA (n39).  
 
 
Results for the second 50 serum samples. 
A second set of 50 serum samples was then examined (Table 6; S4 Fig; S5 Fig). Some 15 of the antigen/antibody 
combinations giving good culture positive PTB/culture negative distinction with the first 50 samples were included in this study, 
together with an additional set of antigens covering different structural types of MA. In general, the results with the second set 
of samples were in agreement with the first set, though in some cases AUC values were rather higher (n4, 0.84 compared to 
0.73; n32, 0.86 compared to 0.69) or lower (n2, 0.79 compared to 0.92), probably due to the small sample sets. All of the 
antigen-secondary antibody combinations again gave a significant difference between smear and culture positive PTB and 
culture negative sets (p <0.05) (Table 6). With this set of samples, both commercial natural human (n15) and bovine TDM 
(n20) give slightly higher AUCs using IgG secondary antibody than with the first set, the bovine TDM performing slightly better 
(AUC 0.90).  
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Table 6: Results of the ELISA with second set of 50 sera [17 culture positive PTB and 33 culture negative patients] using the different combinations of compounds and antibodies.  
     TB  No TB       
Type of 
compound¥¥ 
Compound 
number 
Method# 
Serum 
Dilution 
2nd Ab 
used 
Smear and 
culture 
positive 
PTB  
 
Culture 
negative 
 p value of the 
comparisons of 
medians ELISA 
results from 
culture positive 
PTB and culture 
negative samples 
ROC AUC¥ 
(95 % interval) 
 
Optimum 
Cut-off 
from ROC 
 
Sensitivity/ 
Specificity 
from optimum 
ROC cut-off 
Previous 
AUC as in 
Table 5 
     
Median 
absorbance 
IQR Median 
absorbance 
IQR 
 
Significance 
relative to n15  
  
 
Human 
TDM 
Natural 
mixture 
n15 1: 20 IgG 3.11 2.93 – 3.36 1.51 0.99 – 2.47 <0.001 0.89  (0.80-0.99) 2.88 82/88 0.86 
Bovine 
TDM 
Natural 
mixture 
n20 1: 20 IgG 3.2 2.93 – 3.34 1.66 1.09 – 2.24 <0.001 
0.90  (0.82-0.99) 
2.45 88/88 0.88 
α TDM 6 n3 1: 20 IgG (Fc) 3.14 2.99 – 3.7 1.1 0.54 – 2.34 <0.001 0.83  (0.71-0.94) 2.97 76/85 0.89 
α TMM 7 n4 1: 20 IgG (Fc) 3.21 1.69 – 3.49 0.89 0.39 – 1.39 <0.001 0.84  (0.73-0.95) 1.54 82/79 0.73 
tαTDM 8 n25 1: 20 IgG (Fc) 2.91 2.0 – 3.37 0.75 0.41 – 1.61 <0.001 0.87  (0.77-0.97) 1.12 100/67  
tαTMM 9 n26 1: 20 IgG (Fc) 3.17 1.73 – 3.51 0.73 0.39 – 1.46 <0.001 0.85  (0.74-0.96) 0.99 94/67  
tαTDM 10 n45 1: 80 IgG (Fc) 2.04 0.64 – 2.97 0.46 0.31 – 0.93 0.010 0.74* (0.58-0.90) 1.11 64/81  
tαTMM 11 n46 1: 80 IgG (Fc) 0.74 0.42 – 2.77 0.29 0.21 – 0.86 0.020 0.71** (0.55-0.87) 0.28 93/50  
MeOTDM 12 n28 1: 20 IgG (Fc) 3.12 1.43 – 3.51 0.51 0.41 – 1.52 <0.001 0.86  (0.75-0.97) 2.49 71/94 0.89 
MeOTMM 13 n32 1: 20 IgG (Fc) 2.91 1.68 – 3.14 0.74 0.39 – 1.33 <0.001 0.86  (0.75-0.96) 2.36 65/94 0.69 
MeOTDM 14 n1 1: 20 IgG (Fc) 3.23 2.24 – 3.43 0.48 0.29 – 1.19 <0.001 0.86  (0.75-0.97) 1.25 88/82 0.94 
  n1b 1: 80 IgG (Fc) 1.44 0.52 – 2.34 0.24 0.19 – 0.42 <0.001 0.85  (0.70-0.99) 0.47 93/81 0.86 
MeOTMM 15 n2 1: 20 IgG (Fc) 2.84 0.99 – 3.24 0.6 0.28 – 1.08 <0.001 0.79  (0.65-0.93) 1.49 65/85 0.92 
tMeOTDM 16 n47 1: 80 IgG (Fc) 1.95 1.13 – 3.26 0.37 0.26 – 0.62 <0.001 0.91  (0.82-0.99) 0.70 93/78 0.90 
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tMeOTMM 17 n37 1: 20 IgG (Fc) 3.15 1.45 – 3.22 0.9 0.44 – 2.45 <0.001 0.80  (0.67-0.93) 2.88 71/84 0.88 
tKTDM 18 n5 1: 20 IgG (Fc) 3.13 2.0 – 3.52 0.68 0.45 – 1.28 <0.001 0.89  (0.80-0.98) 1.34 94/79 0.82 
tKTMM 19 n6 1: 20 IgG (Fc) 3.24 2.42 – 3.68 0.96 0.52 – 2.26 <0.001 0.80  (0.67-0.93) 1.18 94/61 0.88 
KTDM 20 n39 1: 20 IgG (Fc) 3.25 3.0 – 3.66 0.64 0.29 – 1.06 <0.001 0.91  (0.83-1.00) 2.59 88/88 0.95 
KTMM 21 n48 1: 80 IgG (Fc) 2.58 0.65 – 3.29 0.39 0.22 – 0.74 <0.001 0.83  (0.69-0.97) 1.50 64/91  
Alkene 
TDM 
22 n40 1: 20 IgG (Fc) 3.15 2.41 – 3.74 0.86 0.51 – 2.3 <0.001 0.82  (0.71-0.94) 1.40 94/73  
α MeOTDM 25 n49 1: 80 IgG (Fc) 2.58 0.97 – 3.06 0.37 0.25 – 0.69 <0.001 0.81  (0.67-0.96) 0.60 93/69  
Footnotes: # Method: as for Table 5   ¥ ROC analyses are presented in S4 Fig. Standard significance values indicated by stars (* P<0.05, ** P<0.01, *** P<0.001) are for comparisons of ROC 
results for each method relative to those for method n15. Significance of pairwise differences between AUC values estimated using the DeLong’s test [67] implemented in the pROC R package. 
Abbreviations: Ab: antibody.  ROC: receiver operator characteristics AUC: area under curve PTB: pulmonary tuberculosis IQR: interquartile range. ¥¥ Compound description as per Table 5. 
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A number of additional antigens were also tested with this set (Table 6). Again, all the antigen-secondary antibody 
combinations responses associated with smear and culture positive PTB rather than culture negative sets. The ROC AUCs 
ranged from 0.71 to 0.87 (S4 Fig). Within this set, no method was significantly better than using natural human TDM and IgG 
secondary antibody.  
Combined results for the first 100 serum samples.  
The results for a sub-set of antigens for the whole set of the first 100 samples were combined (Table 7; Fig 3). All antigen-
secondary antibody combinations give a significantly higher response with smear and culture positive PTB than culture 
negative sets. In agreement with what was reported above, one of the antigens, 20 (method n39), gives a rather better 
discrimination between culture positive PTB and culture negative, with an AUC of 0.94, than the natural human or bovine 
mixtures (0.88 and 0.89), and antigen 16 (n47), AUC 0.91, performs almost as well (S6 Fig).  
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Table 7: Combined results of the ELISA with the two sets of 50 sera (27 culture positive PTB  and 73 culture negative  patients) using selected antigen/antibody combinations  
   TB  No TB        
Antigen or 
compound 
number 
Method# Secondary 
antibody 
Smear and 
culture 
positive PTB 
 Culture 
negative 
 p value## 
 
ROC AUC 
 
(95 % interval) 
Optimum 
Cut-off 
from ROC 
Optimum 
Sensitivity/ 
Specificity 
combination 
from ROC 
Cut-off for 
100% 
sensitivity 
Specificity
Based on 
this cut-off 
   Median 
absorbance 
IQR Median 
absorbance 
IQR  Significance 
relative to n15 
    
Human TDM n15 IgG (whole) 3.11 2.92 -3.37 1.72 1.09 – 2.7 <0.001 0.88  (0.80-0.95) 2.88 78/86 >1.81 51 
Bovine TDM n20 IgG (whole) 3.1 
 
2.86 – 3.34 1.69 
 
1.08 – 2.31 <0.001 0.89  (0.83-0.96) 2.45 
 
89/81 
 
>1.93 58 
6 n1 IgG (Fc ) 3.14 2.47 -3.58 0.99 0.54-1.79 <0.001 0.87  (0.80-0.94) 1.26 89/81 >0.54 38 
7 n3 IgG (Fc ) 2.9 1.59 -3.41 0.95 
 
0.53-2.04 <0.001 0.80 (0.71-0.89) 1.72 
 
89/74 
 
>1.15 59 
12 n4 IgG (Fc ) 2.78 1.63 -3.21 0.69 
 
0.43 – 1.43 <0.001 0.88  (0.80-0.95) 1.38 
 
85/64 
 
>0.62 38 
13 n32 IgG (Fc ) 2.71 1.04 -3.14 0.7 
 
0.47 – 1.25 <0.001 0.81  (0.71-0.91) 2.14 
 
59/93 
 
>0.37 12 
14 n28 IgG (Fc ) 3.25 2.07 – 3.55 0.72 
 
0.4 – 1.19 <0.001 0.90  (0.83-0.96) 1.25 
 
89/81 
 
>0.61 44 
14 n1b IgG (Fc ) 1.1 0.49 – 2.45 0.3 
 
0.22 – 0.42 <0.001 0.86  (0.76-0.96) 0.47 
 
79/81 
 
>0.14 1 
15 n2 IgG (Fc ) 2.84 1.25 – 3.37 0.62 0.41 – 1.17 <0.001 0.83  (0.73-0.93) 1.52 
 
70/86 
 
>0.22 3 
16 n47 IgG (Fc ) 1.51 
 
0.86-3.27 0.37 
 
0.27-0.57 <0.001 0.91  (0.86-0.97) 0.49 96/72 
 
>0.46 62 
17 n37 IgG (Fc ) 2.97 
 
1.41 -3.21 0.71 
 
0.4 – 1.44 <0.001 0.84  (0.77-0.92) 0.77 
 
100/56 
 
>0.22 49 
18 n5 IgG (Fc ) 2.99 
 
1.95 – 3.4 0.82 
 
0.46 -1.47 <0.001 0.87  (0.79-0.94) 1.92 
 
78/82 
 
>0.84 53 
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19 n6 IgG (Fc ) 3.24 2.24 – 3.78 0.97 0.56 – 1.93 <0.001 0.84  (0.75-0.93) 1.79 85/74 >0.44 14 
20 n39 IgG (Fc ) 3.25 
 
2.97 -3.66 0.64 
 
0.34 – 1.24 <0.001 0.94 (0.89-0.98) 1.32 
 
100/75 
 
>1.39 77 
Footnotes:# Method: as for Table 5.  ## Comparison of medians ELISA results from culture positive PTB and culture negative samples.  Abbreviations: PTB: pulmonary tuberculosis;     IQR: 
interquartile range. Ab: antibody, TDM: trehalose dimycolate, TMM: trehalose monomycolate ROC: receiver operator characteristics AUC: area under curve TB: tuberculosis    
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Fig 3. The distribution of responses (absorbances) from the first 100 serum samples from patients with culture 
positive PTB or culture negative (no TB). Each method n15 - n39 is described in Table 7. The bars indicate the medians. 
In each case the secondary antibody was peroxidase conjugated and the binding was measured by addition of o-
phenylenediamine and H2O2 in citrate buffer and the colour reaction was terminated by the addition of acid. Each individual 
measurement was carried out in quadruplicate.  The bars indicate the medians.
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Analysis of the responses for each individual antigen to each of the sera showed subtle differences in pattern. The results 
from seven antigen/secondary antibody combinations (n15, n20, n3, n28, n32, n1, n39), were therefore combined using a 
Random Forest classifier and principal co-ordinate analysis of case proximity, leading to the distribution shown in Fig 4. The 
two axes represent different combinations of the results with each of the antigens. Two clear groups can be identified, one in 
the top left hand corner for the bulk of smear and culture positive PTB samples, the other in the top right for culture negative, 
no TB,  samples; in between was a region containing both sets of samples. Using Generalized Boosted Regression Models 
(GBM) statistics to combine the results from the 7 antigen/antibody combinations provided a prediction of culture positive 
PTB/culture negative to best match the WHO/TDR diagnosis as a rank order from 0 – 1, predicting the likelihood that the 
sample was culture positive PTB (0 very unlikely, 1 very likely). By setting the value of the cut-off for a positive assignment at 
0.24, a sensitivity of 100% and a specificity of 89 % was achieved. Sensitivity+specificity was maximised with a cut-off of 0.35; 
the sensitivity was 96% and the specificity 95% (Table 8). A ROC analysis of these combined data gave an AUC of 0.98 (S7 
Fig).  
Fig 4. Proximity of individual cases using a Random Forest classifier [63] trained with the absobance for the antigens 
n15, n20, n3, n28, n32, n1, n39 for the 100 sample data set in R [64]. Proximities were reduced to 2-dimensions using 
multidimensional scaling. Dimensions 1 and 2 can be interpreted as weighted statistical combinations of the absorbances 
for each serum sample with the antigens. Abbreviations: as for Fig 3. 
Table 8: Predictive value of a statistical combination of the responses for methods n15, n20, n3, n28, n32, n1, n39 
using the initial 100 samples with GBM statistics.  
Cut off used for culture 
positive PTB using 
GBM output 
 
 
>0.24 
 
 
>0.35 
Sensitivity (%) 100 96 
Specificity (%) 89 95 
True positive 27 26 
False positive 8 4 
True negative 65 69 
False negative 0 1 
Total 100 100 
PPV 77 87 
NPV 100 99 
Footnotes: A ROC analysis of the numerical predictions (in range 0 (culture negative) to 1 (smear and culture positive PTB)) 
for each serum sample combined using GBM statistics gave an AUC of 0.98 (see S7 Fig). NPV: negative predictive value. 
PPV: positive predictive value.   
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To set-up a cut-off for the “blind-study” we used the optimal combination of sensitivity and specificity provided by a ROC 
analysis for the first 100. In addition we evaluated the sensitivity and specificity produced by setting the minimum cut-off for 
each antigen to provide 100% sensitivity for these samples (Table 7).   
 
A blind study of 249 serum samples.  
Having established that the synthetic antigens do provide responses in ELISA that match well with the diagnosis of smear and 
culture positive PTB, and that the results from more than one antigen could be combined to enhance the sensitivity and 
specificity, the method was applied in a blind study of an additional 249 serum samples from presumptive TB patients from 
the TDR TB Specimen Bank (Table 9; Fig 5, S8 Fig).  Patients were enrolled as specified in the Material and Methods section. 
Note that in a number of cases, the patients are recorded as having either a history of previous TB, and/or of Bacillus Calmette–
Guérin (BCG) vaccination, and/or having been affected by a recent or current co-infection (e.g. malaria).
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Table 9: Results of the blind analysis of the ELISA for 249 sera (75 culture positive PTB  and 174 culture negative  patients) using selected combinations of compounds and 
antibodies.  
   TB  No TB       
Antigen or 
compound 
number 
Method# Secondary 
antibody 
Culture 
positive 
PTB$ 
 Culture 
negative 
 P## ROC AUC¥ 
 
(95 % interval) 
Sensitivity/ 
Specificity from 
optimum cut-off 
from ROC on 
first 100 samples 
Cut-off based 
on first 100 
samples to 
give 100% 
sensitivity 
Sensitivity/ 
Specificity 
with that 
cut-off 
   Median IQR Median IQR      
Human TDM n15 IgG 3.17 2.48-3.43 1.46 0.91 – 2.46 <0.001 0.80  (0.75-0.86) 64/84 >1.81 83/61 
Bovine TDM n20 IgG 3.18 2.41 – 3.43 1.29 0.79 – 2.17 <0.001 0.84 (0.79-0.89) 73/79 >1.93 80/71 
6 n3 IgG (Fc) 3.55 
 
2.25 – 4.0 0.84 
 
0.51 – 1.47 <0.001 0.87*** (0.83-0.92) 81/79 >1.15 92/70 
12 n28 IgG (Fc) 3.09 
 
1.86 – 3.51 0.73 
 
0.42 – 1.45 <0.001 0.83 (0.77-0.89) 80/72 >0.61 91/40 
13 n32 IgG (Fc) 2.83 
 
1.3 – 3.35 0.69 
 
0.41 – 1.22 <0.001 0.83  (0.77-0.89) 65/87 >0.37 95/22 
14 n1 IgG (Fc) 3.21 
 
2.14 – 3.72 0.65 
 
0.43 – 1.25 <0.001 0.88*** (0.84-0.93) 84/75 >0.54 96/37 
20 n39 IgG (Fc) 3.43 
 
2.07 – 4.0 0.51 
 
0.32 – 0.92 <0.001 0.90*** (0.86-0.95) 83/84 >1.39 83/85 
Footnotes: # Method:  as for Table 5. $ 73 of 75 were also smear positive  ## Comparison of medians from culture positive PTB and culture negative samples. The serum dilution used was 1:20.   
¥ ROC analyses for these samples after unblinding are presented in S8 Fig. Standard significance values indicated by stars (* P<0.05, ** P<0.01, *** P<0.001) are for comparisons of ROC 
results for each method relative to those for method n15. Significance of pairwise differences between AUC values was estimated using the DeLong’s test [67] implemented in the pROC R 
package. Abbreviations: PTB: pulmonary tuberculosis.  IQR: interquartile range. Ab: antibody, TDM: trehalose dimycolate, TMM: trehalose monomycolate ROC: receiver operator characteristics 
AUC: area under curve.   
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Fig 5. The distribution of responses (absorbances), with medians, in the ELISA assay with the third set of 249 samples 
using 7 different antigens, natural TDM from MTB (n15), natural bovine TDM (n20) and five synthetic antigens the 
medians for which are presented in Table 9. The assay was run blind and then un-blinded for analysis compared to cut-off 
values set for the first 100 samples as in Table 7. Method: as for Fig 3.  Abbreviations:  TDM: trehalose dimycolate.   
 
Using cut-off values set prior to the blind study, the sensitivity, specificity and ROC AUC for the natural mixtures of human 
TDM were 64%, 84% and 0.80 and for the bovine TDM were 73%, 79%, and 0.84 respectively. Three of the synthetic antigens 
performed better, antigen 20 (n39) giving a sensitivity of 83%, a specificity of 84%, and an AUC of 0.90. For comparison, with 
the GBM classifier set at the cut-off to achieve 100% sensitivity based on the 100 sample training, a sensitivity of 81%, 
specificity of 86% and an AUC of 0.83 resulted, while setting a cut-off to achieve maximum sensitivity+specificity gave values 
of 74%, 87% and 0.81 repectively. 
 
The results for the complete set of 349 sera.  
Having determined the results for the 249 samples in the above blind study, the data for all 349 samples were then combined 
(Fig 6, S9 Fig). All the synthetic MA sugar ester-secondary antibody combinations showed a significant difference between 
smear and culture positive PTB and culture negative sets (p <0.001), with AUCs of 0.84 – 0.91 (Table 10); in comparison, the 
free MA 26 (Table 4) gave much lower median absorbances and an AUC of just 0.57.  
Fig 6. ELISA responses (absorbances) and medians of smear and culture positive PTB and culture negative sets for 
all 349 samples using 8 different antigens, natural TDM from MTB (n15), natural bovine TDM (n20) and six synthetic 
antigens with secondary antibodies as described in Table 9. The ROC analysis is given in S9 Fig. Method: as for Fig 3.   
Abbreviations:  TDM: trehalose dimycolate. Mtb: Mycobacterium tuberculosis.   
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Table 10: Median values for absorbances of all 349 serum samples   
  TB  No TB     
Antigen or 
compound 
number    
Method# Culture 
positive 
PTB$ 
Median 
 
IQR Culture 
negative 
Median 
 
IQR p 
value 
ROC AUC ¥  
 
(95 % interval) 
Sensitivity/ 
specificity 
from ROC 
analysis 
Human 
TDM 
n15 3.15 2.5-3.4 1.55 0.9-2.5 <0.001 0.82  (0.77-0.87) 68/85 
Bovine 
TDM 
n20 3.17 2.5-3.4 1.41 0.9-2.2 <0.001 0.85* (0.81-0.89) 78/79 
 
6 n3 3.40 2.3-4.0 0.90 0.5-1.6 <0.001 0.87** (0.83-0.91) 84/77 
12 n28 3.03 1.8-3.5 0.72 0.4-1.4 <0.001 0.84  (0.79-0.89) 75/84 
13 n32 2.83 1.1-3.3 0.70 0.4-1.2 <0.001 0.83  (0.77-0.88) 63/90 
14 n1 3.24 2.1-3.7 0.68 0.4-1.2 <0.001 0.89*** (0.85-0.93) 79/89 
20 n39 3.36 2.3-3.9 0.55 0.3-1.0 <0.001 0.91*** (0.87-0.94) 91/79 
26 n44 1.21 0.7-1.8 1.0 0.6-1.5 0.031 0.57*** (0.51-0.64) 38/77 
Footnotes: # Method:  as for Table 5. $ 100 of 102 were also smear positive. For free MA, 26, n44, IgG(whole).  ¥ ROC 
analyses are presented in S9 Fig. Abbreviation: IQR, inter-quartile range.  
A statistical combination of the results from all the antigen-antibody combinations (except for n44), using a Random Forest 
classifier, led to a principal co-ordinate analysis that allowed a distinction between culture positive PTB and culture negative 
(Fig 7) with a ROC AUC of 0.95. For this set of samples 100 of the 102 culture positive PTB samples were both smear and 
culture positive. Two were smear negative, culture positive; both identified as positives in the above assays. 
Fig 7. Proximity of individual cases using a Random Forest classifier [59] trained with the absorbances with the 349 
serum samples for the antigens n15, n20, n3, n28, n32, n1, n39. The ROC AUC for this analysis based on the principal 
co-ordinate (x-axis) compared to PTB or no PTB diagnosis was 0.95.   AUC: area under curve 
  
A more detailed analysis of the individual results showed that, with the cut-off values set by ROC analysis of the initial 100 
samples (Table 7), 73 of the 102 samples diagnosed as samples from culture positive PTB patients, were above the cut-off 
for all antigens used (except method n44) and a further 12 were above the cut-off for six of the seven antigens.  
 
An analysis of the effect of country of origin and other sub-groups is presented in the Supplementary Data (S10-20 Table; 
S11-19 Fig) but must be considered with caution due to lack of standardisation and quality assurance in data collection.  
 
Discussion  
We set-up a serological test for the diagnosis of TB. Using ELISA with two initial sets of 50 serum samples from patients with 
presumptive TB [60], we showed that a number of combinations of a defined single synthetic trehalose di- and mono-mycolate 
antigen and a secondary antibody gave a better distinction than complex natural mixtures of TDM between patients who were 
diagnosed with smear and culture positive PTB, and those who were  negative in culture. The sensitivity and specificity, and 
the pattern of responses, in each case depended on the detailed structure of the antigen and on the secondary antibody used. 
By combining the results from a set of individual antigens using GBM statistics, the distinction could be increased to provide 
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a sensitivity and specificity of 100% and 89% respectively and a ROC AUC of 0.98, meeting the criteria of the WHO target 
product profile [13]. 
In these initial studies with some 38 combinations of synthetic trehalose ester and secondary antibody, 14 with the complete 
set of 100 samples, TDMs and TMMs derived from the common classes of MA in Mtb (α-, keto- and methoxy-MA), all gave 
ROC AUCs above 0.85 using IgG or IgG(Fc) secondary antibodies. Among the antigens evaluated, two gave a better 
discrimination between smear and culture positive PTB and culture negative sets, with AUCs of 0.94 and 0.91, than natural 
human mixture (0.88). 
To validate these results, an additional 249 samples were run blind, using cut-off values set studying the initial 100 samples. 
An optimal sensitivity and specificity combination of 88% and 83% for a single synthetic antigen/secondary antibody 
combination (n5) was obtained; a number of the synthetic antigen/secondary antibody combinations gave a better distinction 
than natural TDM. In contrast, the free MA 26 (method n44) showed a ROC value of just 0.57. 
All of the patients whose sera were included in this study presented with presumptive TB [60] and the majority presented at 
health facilities in countries with high burdens of TB. They were thus representative of populations in which a rapid TB 
diagnostic would be deployed. Combining the results for all 349 samples, we show that an ELISA based on the responses of 
serum antibodies to trehalose esters of single synthetic MA, using IgG(Fc) secondary antibody, was more accurate for TB 
diagnosis than similar assays using natural mixtures of TDMs.  
Moreover, the combination of the results obtained using more than one antigen with the full set of 349 samples again further 
improved the accuracy of the assay. By using principal co-ordinate analysis, the combination of the results from 7 antigens 
led to a 2D-plot in which the results for serum samples from smear and culture positive PTB/culture negative (no TB) patients 
clearly appeared in different areas, with a number in the region between these extremes. This effect of using a set of antigens 
is in contrast to recent reports of the use of a multiple set of protein antigens, where little improvement was observed [70]. The 
reason for this is not yet clear, but may reflect increased structural diversity of binding sites between the different lipid antigens 
compared to protein antigens. 
 
Among the samples tested, no serological response to any antigen was found in 7 samples that were culture positive, bringing 
the performance of the assay below the optimum WHO target product profile [13]. A number of factors, separately or 
collectively, could account for these very low responses relative to the culture negative set. Thus, the samples came from a 
banked set and some may have degraded in storage and use, the disease at the time the serum sample was taken may not 
have progressed to antibody production, levels of antibodies to lipids may fluctuate during active disease as antibodies to 
protein antigens are known to do [14-16,53], or there may be differences in response from one country or region or from one 
population to another.  Differences may also be affected by Mtb lineage and strain. Moreover, it is known that antibody 
responses in patients without TB  can be heterogeneous [53]. A very low serological response in some TB patients has been 
shown in studies using natural TDM [28], and the responses have been associated with the time of clinical onset of symptoms 
[29]. 
Co-infection with HIV is reported not to interfere with serodiagnostic TB assays using either natural TDM [30-41] or natural 
MA mixtures [42-45]. Although the TDR TB Specimen Bank contains sera from HIV-positive patients with symptoms 
suggestive of PTB, no such sera were included in this initial study; a further study to evaluate the assay with defined synthetic 
antigens in TB/HIV co-infected serum is on-going. Further work is also required to optimise the combination of synthetic MA 
based antigens, for example to include the more challenging smear negative samples and to remove the chance of false 
positives from other mycobacterial infections [71], as well as applying it in a rapid, reliable and robust testing format.    
In conclusion, within the set of 349 serum samples selected from different countries, an assay based on the antibody detection 
against selected individual sugar esters of synthetic MAs had a higher accuracy to distinguish smear and culture positive PTB 
from smear and culture negative patients, than did the complex natural mixture of natural TDMs, and gave responses that 
depended on the specific structure of the antigen. By combining the results from more than one synthetic antigen, e.g, including 
different structural classes of MA, the performance of the assay could be further improved. This is in contrast to some multiplex 
assays using protein antigens [70,72], perhaps reflecting differences in antibody-lipid interactions from antibody-protein 
interactions. This study has identified new antigens based on trehalose esters of synthetic MA that are promising candidates 
for diagnostic tests. They can be produced consistently to a high purity in large quantities and thus have advantages over 
many other types of antigen with diagnostic potential. We have shown that using them in combination (in a panel) provides 
better diagnostic performance than using individual antigens, and that the results in ELISA are dependent on the secondary 
antibody.  
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Numerous studies have described delay in the diagnosis and treatment of tuberculosis and the key contribution of poor 
diagnostic capacity at the lower levels of the health services of disease-endemic areas where the majority of TB patients 
present [73]. The economic burden that this delay places on people seeking diagnosis is enormous.  A recent study reported 
that the total costs of TB to patients in low and middle-income countries was equivalent, on average, to 39% of annual 
household income [74]. Half the total cost was incurred before treatment. New, more accessible TB diagnostics are required 
that can bring diagnosis and prompt treatment to the health centres where most patients initially present with their symptoms.  
Even if a simple, rapid TB test could only diagnose patients with smear positive disease it could be a significant step forward 
in TB control.  It would take TB diagnosis to settings where no sputum smear microscopy currently exists or where smear 
microscopy labs are overburdened, under-resourced or of poor quality.     
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